相关实验视频
Updated: May 24, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
预测者达到最小的表现或更好的状态在眼部肌痛性肌痛症与免疫治疗的预测
Teppei Komatsu1, Haruhiko Motegi2, Masahiro Mimori2
1Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-Ku, Tokyo, 105-8461, Japan. teppeinoieni.coicoi@jikei.ac.jp.
眼部肌痛性肌痛性肌痛症 (MG) 的早期免疫疗法显著改善了治疗结果. 在症状出现后的255天内迅速启动治疗对于在眼部MG患者中实现最小的症状或更好的状态至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
背景情况:
- 眼部骨髓灰质炎 (MG) 显著影响生活质量,影响视力和日常活动.
- 免疫疗法是主要的治疗方法,但启动的最佳时间尚未确定.
研究的目的:
- 确定在眼部MG患者中实现最小表现 (MM) 或更好的状态的预测因素.
- 评估早期免疫治疗干预对治疗结果的影响.
主要方法:
- 对48名眼部MG患者的回顾性分析.
- 基于MM或更高地位的成就进行分类.
- 统计分析包括单变量,ROC和多变量逻辑回归.
主要成果:
- 34/48名患者实现了MM或更好的状态.
- 在那些实现MM或更好的患者中,从症状发作到免疫治疗的时间显著缩短 (30天与1095天相比).
- 免疫疗法启动的255天截止时间显示高灵敏度 (92.9%) 和特异性 (91.2%) 达到MM或更好的状态.
结论:
- 早期启动免疫疗法 (在255天内) 是实现MM或眼部MG更好的状态的关键预测因素.
- 及时诊断和治疗对于优化患者的治疗结果至关重要.
- 这些发现支持及时干预,以改善眼部MG患者的生活质量.
更多相关视频
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
相关概念视频
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Accessory Structures of the Eye
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...